Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the long-term safety of tegaserod in women with symptoms
of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice
daily.